HealthInvest Partners AB Boosts Position in Autolus Therapeutics plc (NASDAQ:AUTL)

HealthInvest Partners AB boosted its position in Autolus Therapeutics plc (NASDAQ:AUTL) by 8.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 479,644 shares of the company’s stock after purchasing an additional 37,221 shares during the period. HealthInvest Partners AB owned about 0.18% of Autolus Therapeutics worth $1,060,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in AUTL. Bellevue Group AG boosted its holdings in shares of Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after buying an additional 9,000 shares during the last quarter. State Street Corp lifted its position in Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after purchasing an additional 10,401 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 3rd quarter valued at about $51,000. HighVista Strategies LLC lifted its holdings in Autolus Therapeutics by 2.7% during the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after purchasing an additional 14,204 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Autolus Therapeutics by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after buying an additional 14,959 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $1.95 on Monday. Autolus Therapeutics plc has a 52-week low of $1.87 and a 52-week high of $6.63. The firm’s fifty day moving average is $2.23 and its 200 day moving average is $3.18. The company has a market cap of $518.88 million, a price-to-earnings ratio of -1.61 and a beta of 2.02.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.